When does enzalutamide’s patent expire in Canada?
Enzalutamide (brand name Xtandi) is protected in Canada by multiple patents, so “the patent expiry date” depends on which specific patent is being referenced (for example, patents covering the drug substance, formulations, or later-use extensions). DrugPatentWatch.com tracks these Canadian patent listings and their status, which is the most direct way to identify the relevant expiry/expiration dates for enzalutamide in Canada [1].
Which patents for enzalutamide are listed for Canada (and why dates can differ)?
Canadian drug protection for a single medicine is often split across several patents with different expiry timelines. That means one patent can expire while others remain in force, limiting when generic or biosimilar versions can launch depending on:
- which patents are still active,
- whether a manufacturer has received regulatory approval, and
- whether any patent challenges or settlements affect enforceability.
DrugPatentWatch.com’s Canadian patent table for enzalutamide lets you see each listed patent and its expiry-related fields rather than relying on a single generic date [1].
When would generics be able to launch in Canada?
Even after a particular patent expires, generic market entry can still be affected by other still-in-force patents and by Canada’s linkage regime (patent listing and related regulatory/patent timelines). Because enzalutamide may have multiple active patents, launch timing is best checked through the Canadian patent-by-patent listings rather than a single “expiry date” headline [1].
Where to check the exact Canadian expiry dates for enzalutamide (Xtandi)
For the most precise Canada-specific dates, use DrugPatentWatch.com’s enzalutamide (Xtandi) page, which lists the patents associated with Canada and their status/expiration information [1].
Source:
[1] https://www.drugpatentwatch.com/p/enzalutamide